• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

1805833-75-3 (CT7001)

1

Identification

CT7001 CT7001
Name CT7001
Formula C22H30N6O
MW 394.5132
CAS No. 1805833-75-3
EINECS
Smiles O[[email protected]]1CNCC[[email protected]@H]1CNC2=NC3=C(C(C)C)C=NN3C(NCC4=CC=CC=C4)=C2
Synonyms ICEC0942
InChI InChI=1S/C22H30N6O/c1-15(2)18-13-26-28-21(25-11-16-6-4-3-5-7-16)10-20(27-22(18)28)24-12-17-8-9-23-14-19(17)29/h3-7,10,13,15,17,19,23,25,29H,8-9,11-12,14H2,1-2H3,(H,24,27)/t17-,19+/m1/s1
2

Introduction

CT7001 is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively.

Background Information

ICEC 0942 (CT7001) is a potent, selective, orally active CDK7 inhibitor with IC50 of 41 nM, displays 15-fold selectivity over CDK2 (IC50=578 nM); displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2, CDK5 and CDK9; demonstrates sensitivity against a wide range of cancer types with GI50 values ranging between 0.2-0.3 uM; shows substantial anti-tumor effects in xenografts of both breast and colorectal cancers, also exhibits complete growth arrest of ER-positive tumor xenografts combined with tamoxifen.Solid TumorsPhase 1 Clinical ......by ProbeChem
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB100127355

Storage condition

Solubility

5

Mechanism and Indication

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
7

Safety Data of CT7001

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
ProbeChem
Shanghai Haoyuan Chemexpress Co., Ltd. China
10

Related Products

Other Forms of 1805833-75-3

Name CAS No Formula MW

Recommended Compounds in CDK

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

CT7001

Tags: buy 1805833-75-3 IC50 | 1805833-75-3 price | 1805833-75-3 cost | 1805833-75-3 solubility | 1805833-75-3 purchase | 1805833-75-3 manufacturer | 1805833-75-3 research buy | 1805833-75-3 order | 1805833-75-3 MSDS | 1805833-75-3 chemical structure | 1805833-75-3 Storage condition | 1805833-75-3 molecular weight | 1805833-75-3 mw | 1805833-75-3 datasheet | 1805833-75-3 supplier | 1805833-75-3 cell line | 1805833-75-3 NMR | 1805833-75-3 MS | 1805833-75-3 IR | 1805833-75-3 solubility | 1805833-75-3 Safe information | 1805833-75-3 Qc and Spectral Information | 1805833-75-3 Clinical Information | 1805833-75-3 Clinical Trial | 1805833-75-3 Route of Synthesis | 1805833-75-3 storage condition | 1805833-75-3 diseases and conditions | 1805833-75-3 flash point | 1805833-75-3 boiling point | 1805833-75-3 melting point | 1805833-75-3 storage condition | 1805833-75-3 brand